Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G
In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
Endocrinology, Vol
Regulatory reforms have shortened approval timelines, encouraging multinational companies to invest and launch products
BPC-157 Apex Biopharma , , BPC-157 (Body Protection Compound)
Newer medications like Tirzepatide also help your body to release insulin more effectively thereby helping to stabilize blood sugar levels